Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
在既往接受过恩福妥单抗治疗的转移性尿路上皮癌患者中,沙妥珠单抗戈维替康的真实世界临床疗效
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105305
Sternschuss, M; Toumbacaris, N; Das, J P; Powles, T; Kotecha, R R; Laccetti, A L; Xiao, H; Feld, E; McHugh, D J; Keegan, N M; Bajorin, D F; Funt, S A; Shah, N J; Iyer, G; Aggen, D H; Teo, M Y; Ostrovnaya, I; Rosenberg, J E